Physician profile
James Mylan Sinclair
NPI 1356300230
$12,551.71
in general payments reported to CMS, 2019-2025
67 companies · $873 in 2025
The $873 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,017 · 2020: $1,434 · 2021: $2,581 · 2022: $1,194 · 2023: $2,351 · 2024: $2,102 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,309 · Education: $16.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,309.12 |
| Education | $16.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,405.99 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Epizyme, INC. | $1,278.78 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $683.00 | 2019-2025 | Ultomiris |
| Genzyme Corporation | $650.85 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $599.71 | 2019-2024 | Imfinzi |
| Amgen INC. | $577.94 | 2019-2022 | |
| Celgene Corporation | $541.01 | 2019-2025 | Reblozyl, Pomalyst, Onureg |
| Daiichi Sankyo INC. | $502.55 | 2020-2025 | Enhertu |
| Ipsen Biopharmaceuticals, INC | $485.00 | 2020-2024 | Tazverik, Onivyde, Somatuline Depot |
| Merck Sharp & Dohme LLC | $452.70 | 2019-2024 | Keytruda, Welireg |
| Novartis Pharmaceuticals Corporation | $402.61 | 2019-2024 | |
| Pfizer INC. | $363.15 | 2019-2025 | |
| Genmab U.S., INC. | $362.81 | 2023-2024 | Epkinly |
| Janssen Biotech, INC. | $339.13 | 2019-2024 | Darzalex, Tecvayli, Erleada |
| Exelixis INC. | $284.70 | 2019-2025 | Cabometyx |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sinclair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.